Arcutis Biotherapeutics has been granted a patent for an improved method of treating inflammatory disorders using a topical roflumilast composition. The composition includes specific ingredients to enhance therapeutic efficacy while reducing side effects. GlobalData’s report on Arcutis Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Arcutis Biotherapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arcutis Biotherapeutics, was a key innovation area identified from patents. Arcutis Biotherapeutics's grant share as of May 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.

Topical roflumilast composition for treating inflammatory disorders

Source: United States Patent and Trademark Office (USPTO). Credit: Arcutis Biotherapeutics Inc

A recently granted patent (Publication Number: US12011437B1) discloses a topical roflumilast pharmaceutical composition. The composition includes roflumilast in a specific concentration range of 0.05-1.0% w/w, water, a hydrophobic component like petrolatum, a solvent containing diethylene glycol monoethyl ether, and a surfactant blend of ceteraryl alcohol, dicetyl phosphate, and ceteth-10 phosphate. The formulation aims to achieve a specific Cmax range between 0.5 ng/ml and 7.34 ng/ml at steady state, with a peak to trough ratio of less than 2.

Furthermore, the patent details variations in the composition, such as different percentages of diethylene glycol monoethyl ether and the surfactant, to achieve the desired pharmacokinetic profile of roflumilast in the blood plasma. The formulation is designed to ensure a Cmax below 3.99 ng/ml at steady state, with a peak to trough ratio of approximately 1. This patent highlights the specific components and concentrations required to optimize the delivery and effectiveness of roflumilast through a topical pharmaceutical composition, offering potential benefits in the treatment of relevant medical conditions.

To know more about GlobalData’s detailed insights on Arcutis Biotherapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies